. Author manuscript; available in PMC: 2018 Jul 1.

Published in final edited form as: Toxicol Appl Pharmacol. 2017 Apr 8;326:34–42. doi: 10.1016/j.taap.2017.04.004

Table 2.

Comparison of Brain Pharmacokinetic Profiles^*

Compound	AEOL11114		AEOL11203
Route	i.p	p.o.	i.p	p.o.
Half-life (h)	2.5 ± 0.7	3.7 ± 1.2	11 ± 4.3	6.5 ± 2.4
AUC (µmol h/L)	20.9 ± 9	9.46 ± 1.21	6.84 ± 0.15	3.14 ± 0.84
Cmax (nM)	490 ± 20	230 ± 11	140 ± 5	50 ± 6.3
Tmax (h)	8.5 ± 1.2	9.9 ± 2.0	11 ± 2.1	15 ± 2.1
Bioavailability (%)	NA	45 ± 6	NA	46 ± 1

Pharmacokinetic data was obtained using a one compartment model with first order input and first order output (PK analyst, model #3, MicroMath, Salt Lake City, UT).

NA, not applicable